Incyte Corporation: PharmaVitae Report

This analysis examines the historical and forecast performance for Incyte in the prescription pharmaceutical sector. The profile encompasses key product analysis and forecasts, pipeline assessment, and evaluation of company strategy and financial performance over a 6-year period.

Features and benefits

• Gain insight into Incyte's strategic outlook across the next 6 years
• Analysis of strategically important company products, supported by patient-based forecasting and key opinion leader interviews

Highlights

Strategic evaluation of Incyte's outlook for the next six years. Assessment of key strengths, weaknesses, opportunities and threats and appraisal of the company’s product portfolio, pipeline and commercial relationships.

Your key questions answered

• Assess the prospects for Jakafi (ruxolitinib), inidcated for myelofibrosis
• See what Jakafi's key competitors will be in the myelofibrosis market

Table Of Contents

ABOUT THIS REPORT
PharmaVitae Explorer database
Chapter structure
Sales and product analysis
Financial analysis
Data sourcing
Analyst consensus

EXECUTIVE SUMMARY
Company introduction
Recent developments
Corporate relationships
Strategic overview
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats

SAND PRODUCT ANALYSIS
Sales overview
Product analysis
Product sales
Jakafi (ruxolitinib)
Disease background
Myelofibrosis clinical trials
Use in myelofibrosis
Competitors in myelofibrosis
Polycythemia vera and essential thrombocythemia clinical trials
Use in polycythemia vera
Use in essential thrombocythemia
Other malignancies
Key forecasting assumptions
Other products
INCB18424 (topical formulation) for psoriasis
INCB24360 for melanoma and ovarian cancers
INCB28060 for solid tumors

FINANCIAL ANALYSIS
Financial performance overview
Operating costs and profit analysis, 2004–10
Operating costs and profit analysis, 2010–16

APPENDIX
References
Exchange rates

List of Tables

Table: Incyte R&D pipeline
Table: Incyte product portfolio overview ($m), 2010–16
Table: Jakafi clinical trials, ongoing
Table: Overview of pivotal Phase III data for Jakafi, 2011
Table: Pipeline myelofibrosis agents
Table: Jakafi US forecast model
Table: Incyte operating revenue/cost analysis ($m), 2004–10
Table: Incyte operating revenue/cost analysis ($m), 2010–16
Table: Exchange rates, 2011

List of Figures

Figure: PharmaVitae Explorer
Figure: Incyte catalyst timeline, 2011–16
Figure: Incyte prescription pharmaceutical performance, sales ($m) and growth rate (%), 2010–16
Figure: Jakafi sales ($m), 2010–16
Figure: Incyte operating revenue/cost performance ($m), 2004–16